We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
Read MoreHide Full Article
Key Takeaways
AbbVie's stock has gained 25.4% in six months, driven by Skyrizi, Rinvoq and neuroscience portfolio growth.
Skyrizi and Rinvoq are expected to generate over $31 billion in combined 2026 sales, supporting growth.
Humira erosion, oncology declines and Aesthetics weakness pose challenges.
AbbVie’s (ABBV - Free Report) stock has risen 25.4% over the past six months, supported by strong growth from its newer medicines and improving confidence in its post-Humira growth profile. Skyrizi and Rinvoq sales rose 26.3% and 22.2%, respectively, in the first half of 2026, while the neuroscience portfolio also delivered strong growth. Investor sentiment also benefited from AbbVie’s acquisition of Apogee Therapeutics, which has strengthened its immunology pipeline, and encouraging pipeline developments such as positive phase III data for etentamig.
Let us understand these factors in detail to make an informed decision on whether to buy, sell or hold AbbVie’s stock at current levels.
AbbVie’s Growth Story Shifts From Humira to Skyrizi, Rinvoq
Sales of Humira, a drug that once generated more than 50% of AbbVie’s total revenues, are declining due to loss of exclusivity (LOE) and biosimilar erosion. However, AbbVie has successfully navigated the Humira LOE period by launching two other successful immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
In 2026, AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion, with $14.6 billion recorded in the first half. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026. Management is particularly positive on Skyrizi and Rinvoq’s competitive positioning in inflammatory bowel disease or IBD indications.
Strong immunology market growth, market share gains and momentum from new indications are expected to drive these drugs’ growth. Rinvoq was approved for two indications — vitiligo and alopecia areata — in the EU in July 2026, while applications are under review in the United States. In addition, phase III data for Rinvoq in hidradenitis suppurativa are expected later this year. AbbVie believes that the vitiligo and alopecia areata indications alone can add up to $2 billion in combined peak sales for Rinvoq.
However, AbbVie expects a low single-digit pricing headwind for both Skyrizi and Rinvoq in 2026 and over the next few years. Moreover, the launch of J&J’s (JNJ - Free Report) new oral pill for moderate-to-severe plaque psoriasis, Icotyde, has increased competitive pressure for Skyrizi, which can impact the product’s prescription trends. However, J&J seems confident that it can navigate competition from Icotyde.
Neuroscience Drugs Emerge as a Key Growth Driver for ABBV
AbbVie’s neuroscience portfolio is also contributing to top-line growth, driven by higher sales of Botox Therapeutic, depression drug Vraylar, newer migraine drugs Ubrelvy and Qulipta, and new Parkinson’s disease drug, Vyalev. AbbVie’s oral CGRPs, Ubrelvy and Qulipta/Aquipta, represent a combined $5 billion-plus peak sales opportunity.
The launch of Vyalev, a transformative therapy for treating advanced Parkinson’s disease, approved in late 2024, has been encouraging, with first-half 2026 sales reaching $457 million. AbbVie expects the therapy to achieve blockbuster status in 2026 as U.S. uptake accelerates following full coverage. AbbVie’s once-daily oral tablet, Juvmo (tavapadon), was approved by the FDA for treating Parkinson's disease last week. With Juvmo, Vyalev and Duopa, AbbVie expects its Parkinson's disease franchise to have peak annual sales potential of more than $5 billion and to be a key neuroscience growth driver.
Pipeline and M&A Expand ABBV’s Growth Opportunities
AbbVie boasts a robust pipeline. Earlier this month, AbbVie announced positive top-line data from the phase III CERVINO study on etentamig for treating third-line-plus multiple myeloma. The study met both of its primary goals, showing that treatment with etentamig significantly improved the objective response rate (ORR) and progression-free survival (PFS) compared with standard available therapies.
Over the next few months, AbbVie expects pivotal data readouts for some other key pipeline candidates like lutikizumab (hidradenitis suppurativa) and Temab-A (metastatic colorectal cancer). In May, the FDA approved Decnupaz/pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm in the United States, and as discussed before, Juvmo was approved by the FDA in September. These new products/pipeline programs have the potential to drive long-term growth for AbbVie, while Skyrizi and Rinvoq should boost near-term growth.
AbbVie is evaluating Skyrizi-based combination regimens with assets like ABBV-382 (anti-α4β7) and ABBV-701 (anti-TL1A) to create best-in-class, durable remission therapies in IBD. It has also filed regulatory applications seeking approval of a subcutaneous induction regimen for Skyrizi in Crohn’s disease, which can improve the drug’s competitive positioning and drive an acceleration in sales, once approved.
AbbVie has been on an acquisition spree over the past couple of years to bolster the early-stage pipeline that should drive long-term growth. It is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience. The latest acquisition of Apogee Therapeutics has added promising dermatology, respiratory and inflammatory disease assets that will strengthen its immunology pipeline and support long-term growth.
ABBV’s Aesthetics Business Faces Continued Headwinds
AbbVie has been seeing soft sales of its Aesthetics unit for the past couple of years. Continued macro challenges and economic headwinds are hurting Aesthetics sales. Global aesthetics sales are projected to be $5 billion in 2026, flat from 2025 levels, as moderate growth in Botox Cosmetic is being offset by continued decline in Juvederm sales due to continued headwinds in key dermal filler markets.
AbbVie’s Humira Erosion & Oncology Headwinds
Sales of Humira are declining due to biosimilar erosion. The launch of Humira biosimilars in the United States in 2023 significantly eroded the drug’s sales in 2024 and 2025. Humira sales declined around 38.2% in the first half of 2026 and should continue to decline in the second half as more plans exclude branded Humira and move to exclusive biosimilar contracts.
AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta. However, its oncology sales have slightly slowed as higher Venclexta sales and contributions from new drugs, Elahere, Epkinly and Emrelis, are being offset by an expected decline in Imbruvica sales. In the second quarter, AbbVie’s oncology sales declined 2.4%. However, AbbVie believes the oncology pipeline is robust with several study readouts and initiations expected this year.
ABBV Stock Price, Valuation and Estimate Revision
ABBV stock has risen 14.6% so far this year compared with an increase of 12.9% for the industry.
ABBV Stock Outperforms Industry
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 16.74 forward earnings, lower than 18.16 for the industry. However, the stock is trading above its five-year mean of 14.15. The stock is cheaper than other large drugmakers like Eli Lilly (LLY - Free Report) , J&J and Merck ((MRK - Free Report) )
ABBV Stock Valuation
Image Source: Zacks Investment Research
Earnings estimates for 2026 have declined from $14.12 to $14.05 over the past 60 days, while those for 2027 have declined from $16.24 to $16.12 over the same time frame.
ABBV Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in ABBV Stock
AbbVie combats its share of headwinds, including the impact of Humira LOE, slowing oncology sales, evolving competitive dynamics for Skyrizi and continued macro woes for Aesthetics. Near-term profitability remains affected by acquired in-process research and development charges related to acquisitions.
However, despite Humira's U.S. patent expiry, AbbVie has successfully replaced much of the blockbuster's lost revenues with strong growth from Skyrizi and Rinvoq, easing concerns over its long-term earnings outlook.
AbbVie expects total revenues to rise around 10% in 2026, backed mainly by significant momentum in immunology and neuroscience products, which are demonstrating significant growth and delivering share gains in growing markets. It expects high single-digit revenue growth through 2029. Investors should retain this Zacks Rank #3 (Hold) stock as its long-term prospects remain intact. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
Key Takeaways
AbbVie’s (ABBV - Free Report) stock has risen 25.4% over the past six months, supported by strong growth from its newer medicines and improving confidence in its post-Humira growth profile. Skyrizi and Rinvoq sales rose 26.3% and 22.2%, respectively, in the first half of 2026, while the neuroscience portfolio also delivered strong growth. Investor sentiment also benefited from AbbVie’s acquisition of Apogee Therapeutics, which has strengthened its immunology pipeline, and encouraging pipeline developments such as positive phase III data for etentamig.
Let us understand these factors in detail to make an informed decision on whether to buy, sell or hold AbbVie’s stock at current levels.
AbbVie’s Growth Story Shifts From Humira to Skyrizi, Rinvoq
Sales of Humira, a drug that once generated more than 50% of AbbVie’s total revenues, are declining due to loss of exclusivity (LOE) and biosimilar erosion. However, AbbVie has successfully navigated the Humira LOE period by launching two other successful immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
In 2026, AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion, with $14.6 billion recorded in the first half. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026. Management is particularly positive on Skyrizi and Rinvoq’s competitive positioning in inflammatory bowel disease or IBD indications.
Strong immunology market growth, market share gains and momentum from new indications are expected to drive these drugs’ growth. Rinvoq was approved for two indications — vitiligo and alopecia areata — in the EU in July 2026, while applications are under review in the United States. In addition, phase III data for Rinvoq in hidradenitis suppurativa are expected later this year. AbbVie believes that the vitiligo and alopecia areata indications alone can add up to $2 billion in combined peak sales for Rinvoq.
However, AbbVie expects a low single-digit pricing headwind for both Skyrizi and Rinvoq in 2026 and over the next few years. Moreover, the launch of J&J’s (JNJ - Free Report) new oral pill for moderate-to-severe plaque psoriasis, Icotyde, has increased competitive pressure for Skyrizi, which can impact the product’s prescription trends. However, J&J seems confident that it can navigate competition from Icotyde.
Neuroscience Drugs Emerge as a Key Growth Driver for ABBV
AbbVie’s neuroscience portfolio is also contributing to top-line growth, driven by higher sales of Botox Therapeutic, depression drug Vraylar, newer migraine drugs Ubrelvy and Qulipta, and new Parkinson’s disease drug, Vyalev. AbbVie’s oral CGRPs, Ubrelvy and Qulipta/Aquipta, represent a combined $5 billion-plus peak sales opportunity.
The launch of Vyalev, a transformative therapy for treating advanced Parkinson’s disease, approved in late 2024, has been encouraging, with first-half 2026 sales reaching $457 million. AbbVie expects the therapy to achieve blockbuster status in 2026 as U.S. uptake accelerates following full coverage. AbbVie’s once-daily oral tablet, Juvmo (tavapadon), was approved by the FDA for treating Parkinson's disease last week. With Juvmo, Vyalev and Duopa, AbbVie expects its Parkinson's disease franchise to have peak annual sales potential of more than $5 billion and to be a key neuroscience growth driver.
Pipeline and M&A Expand ABBV’s Growth Opportunities
AbbVie boasts a robust pipeline. Earlier this month, AbbVie announced positive top-line data from the phase III CERVINO study on etentamig for treating third-line-plus multiple myeloma. The study met both of its primary goals, showing that treatment with etentamig significantly improved the objective response rate (ORR) and progression-free survival (PFS) compared with standard available therapies.
Over the next few months, AbbVie expects pivotal data readouts for some other key pipeline candidates like lutikizumab (hidradenitis suppurativa) and Temab-A (metastatic colorectal cancer). In May, the FDA approved Decnupaz/pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm in the United States, and as discussed before, Juvmo was approved by the FDA in September. These new products/pipeline programs have the potential to drive long-term growth for AbbVie, while Skyrizi and Rinvoq should boost near-term growth.
AbbVie is evaluating Skyrizi-based combination regimens with assets like ABBV-382 (anti-α4β7) and ABBV-701 (anti-TL1A) to create best-in-class, durable remission therapies in IBD. It has also filed regulatory applications seeking approval of a subcutaneous induction regimen for Skyrizi in Crohn’s disease, which can improve the drug’s competitive positioning and drive an acceleration in sales, once approved.
AbbVie has been on an acquisition spree over the past couple of years to bolster the early-stage pipeline that should drive long-term growth. It is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience. The latest acquisition of Apogee Therapeutics has added promising dermatology, respiratory and inflammatory disease assets that will strengthen its immunology pipeline and support long-term growth.
ABBV’s Aesthetics Business Faces Continued Headwinds
AbbVie has been seeing soft sales of its Aesthetics unit for the past couple of years. Continued macro challenges and economic headwinds are hurting Aesthetics sales. Global aesthetics sales are projected to be $5 billion in 2026, flat from 2025 levels, as moderate growth in Botox Cosmetic is being offset by continued decline in Juvederm sales due to continued headwinds in key dermal filler markets.
AbbVie’s Humira Erosion & Oncology Headwinds
Sales of Humira are declining due to biosimilar erosion. The launch of Humira biosimilars in the United States in 2023 significantly eroded the drug’s sales in 2024 and 2025. Humira sales declined around 38.2% in the first half of 2026 and should continue to decline in the second half as more plans exclude branded Humira and move to exclusive biosimilar contracts.
AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta. However, its oncology sales have slightly slowed as higher Venclexta sales and contributions from new drugs, Elahere, Epkinly and Emrelis, are being offset by an expected decline in Imbruvica sales. In the second quarter, AbbVie’s oncology sales declined 2.4%. However, AbbVie believes the oncology pipeline is robust with several study readouts and initiations expected this year.
ABBV Stock Price, Valuation and Estimate Revision
ABBV stock has risen 14.6% so far this year compared with an increase of 12.9% for the industry.
ABBV Stock Outperforms Industry
From a valuation standpoint, AbbVie is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 16.74 forward earnings, lower than 18.16 for the industry. However, the stock is trading above its five-year mean of 14.15. The stock is cheaper than other large drugmakers like Eli Lilly (LLY - Free Report) , J&J and Merck ((MRK - Free Report) )
ABBV Stock Valuation
Earnings estimates for 2026 have declined from $14.12 to $14.05 over the past 60 days, while those for 2027 have declined from $16.24 to $16.12 over the same time frame.
ABBV Estimate Movement
Stay Invested in ABBV Stock
AbbVie combats its share of headwinds, including the impact of Humira LOE, slowing oncology sales, evolving competitive dynamics for Skyrizi and continued macro woes for Aesthetics. Near-term profitability remains affected by acquired in-process research and development charges related to acquisitions.
However, despite Humira's U.S. patent expiry, AbbVie has successfully replaced much of the blockbuster's lost revenues with strong growth from Skyrizi and Rinvoq, easing concerns over its long-term earnings outlook.
AbbVie expects total revenues to rise around 10% in 2026, backed mainly by significant momentum in immunology and neuroscience products, which are demonstrating significant growth and delivering share gains in growing markets. It expects high single-digit revenue growth through 2029. Investors should retain this Zacks Rank #3 (Hold) stock as its long-term prospects remain intact. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.